This trial is conducted in Europe. The aim of this trial is characterise the metabolic profile of liraglutide in plasma, urine, and faeces after a single injection of \[3H\]-liraglutide.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
7
A single dose of 0.75 mg will be given as a subcutaneous injection
Novo Nordisk Investigational Site
Groningen, Netherlands
Profile and identity of the major metabolites of tritium labelled liraglutide in plasma, urine, and faeces
Total recovery of tritium, [3H]-liraglutide and metabolites in urine and faeces
Area under the curve
Cmax, maximum concentration
tmax, time to reach Cmax
t½, terminal half-life
The distribution of [3H]-liraglutide in whole blood versus plasma
Adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.